Abstract
Background
Modafinil is a wake-promoting agent that provides wide ranges of neurological effects. There is evidence that it can produce antidepressant effects. This study investigated the antidepressant effect of modafinil in the tail suspension (TST) in mice.
Methods
Different doses of modafinil was intraperitoneally (ip) administrated and then animals were subjected to TST and/or open field test (OFT). Moreover, the implication of the dopaminergic neurotransmission in modafinil’s antidepressant effect was studied. For this purpose, animals were pretreated with haloperidol (non-selective dopamine receptor antagonist), or SCH23390 and sulpiride (the dopamine D1 and D2 receptor antagonist, respectively), then were assessed by TST. The possible effect of sub-effective dose of modafinil in combination with sub-therapeutic doses of standard antidepressants was also evaluated in separate groups.
Results
Modafinil (75 mg/kg, ip) produced antidepressant effect in TST, as compared to a control group, without any alterations in ambulation in OFT. Pretreatment of mice with haloperidol (0.2 mg/kg, ip) and sulpride (50 mg/kg, ip) blocked the anti-immobility effect of modafinil (75 mg/kg, ip). We also found that the administration of SCH23390 (0.05 mg/kg, sc) couldn’t antagonize the antidepressant effects of modafinil. In addition, a sub-effective dose of modafinil (50 mg/kg, ip) potentiated the sub-effective doses of standard antidepressants including of bupropion (1 mg/kg, ip), fluoxetine (1 mg/kg, ip) and imipramine (0.1 mg/kg, ip) and reduced immobility time in TST.
Conclusion
Results show that modafinil induced an antidepressant property in TST and this effect apparently was mediated through interaction with the dopaminergic (D2 receptors) system.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Binfare RW, Rosa AO, Lobato KR, Santos AR, Rodrigues AL. Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(3):530–40.
Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry 2005;58(10):831–7.
Machado DG, Bettio LE, Cunha MP, Capra JC, Dalmarco JB, Pizzolatti MG, et al. Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(4):642–50.
Millan MJ. The role of monoamines in the actions of established and novel antidepressant agents: a critical review. Eur J Pharmacol 2004;500(1–3):371–84.
Basso AM, Gallagher KB, Bratcher NA, Brioni JD, Moreland RB, Hsieh GC, et al. Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 2005;30(7):1257–68.
Gershon AA, Vishne T, Grunhaus L. Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 2007;61(2):145–53.
Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64(3):327–37.
Yadid G, Friedman A. Dynamics of the dopaminergic system as a key component to the understanding of depression. Prog Brain Res 2008;172:265–86.
Farhoudi M, Sadigh-Eteghad S, Andalib S, Vafaee M, Ziaee M, Mahmoudi J. An analytical review on probable anti-parkinsonian effect of modafinil. JARCM 2013;1(2):58–62.
Wisor J. Modafinil as a catecholaminergic agent: empirical evidence and unanswered questions. Front Neurol 2013;4:1–10.
Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006;67(4):554–66.
Sase S, Khan D, Sialana F, Höger H, Russo-Schlaff N, Lubec G. Modafinil improves performance in the multiple T-Maze and modifies GluR1, GluR2, D2 and NR1 receptor complex levels in the C57BL/6J mouse. Amino Acids 2012;43(6):2285–92.
Gerrard P, Malcolm R. Mechanisms of modafinil: a review of current research. Neuropsychiatr Dis Treat 2007;3(3):349–64.
Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 2008;28(34):8462–9.
Cardoso CC, Lobato KR, Binfare RW, Ferreira PK, Rosa AO, Santos AR, et al. Evidence for the involvement of the monoaminergic system in the antidepressant-like effect of magnesium. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(2):235–42.
Gu X, Zhou Y, Wu X, Wang F, Zhang CY, Du C, et al. Antidepressant-like effects of auraptenol in mice. Sci Rep 2014;4:1–4.
Jesse CR, Wilhelm EA, Bortolatto CF, Rocha JB, Nogueira CW. Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the anti-depressant-like effect of bis selenide in the mouse tail suspension test. Eur J Pharmacol 2010;635(1–3):135–41.
Mantovani M, Pertile R, Calixto JB, Santos AR, Rodrigues AL. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci Lett 2003;343(1):1–4.
Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005;29(4–5):571–625.
Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23(5):238–45.
Kafkafi N, Yekutieli D, Elmer GI. A data mining approach to in vivo classification of psychopharmacological drugs. Neuropsychopharmacology 2009;34(3):607–23.
Bobo WV, Shelton RC. Modafinil as an adjunctive treatment for bipolar depression. European Psychiatric Review 2010;3(2):49–52.
Yamada J, Sugimoto Y, Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 2004;504(3):207–11.
Martin-Soelch C. Is depression associated with dysfunction of the central reward system? Biochem Soc Trans 2009;37(1):313.
Keller J, Young CB, Kelley E, Prater K, Levitin DJ, Menon V. Trait anhedonia is associated with reduced reactivity and connectivity of mesolimbic and paralimbic reward pathways. J Psychiatr Res 2013;47(10):1319–28.
Henriques JB, Davidson RJ. Decreased responsiveness to reward in depression. Cogn Emot 2000;14(5):711–24.
Alex K, Pehek E. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Therap 2007;113(2):296–320.
Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 2008;33(2):368–77.
Shirayama Y, Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr Neuropharmacol 2006;4(4):277.
Murillo-Rodríguez E, Haro R, Palomero-Rivero M, Millán-Aldaco D, Drucker-Colín R. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007;176(2):353–7.
Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301(11):1148–54.
Dailly E, Chenu F, Renard CE, Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004;18(6):601–7.
Kalivas PW. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev 1993;18(1):75–113.
Hirano S, Miyata S, Onodera K, Kamei J. Involvement of dopamine D1 receptors and alpha1-adrenoceptors in the antidepressant-like effect of chlorpheniramine in the mouse tail suspension test. Eur J Pharmacol 2007;562(1–2):72–6.
Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2007;33(7):1477–502.
Ikemoto S, Glazier BS, Murphy JM, McBride WJ. Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward. J Neurosci 1997;17(21):8580–7.
Hisahara S, Shimohama S. Dopamine receptors Parkinson’s disease. Int J Med Chem 2011;2011:1–16.
Bachtell RK, Whisler K, Karanian D, Self DW. Effects of intranucleus accumbens shell administration of dopamine agonists and antagonists on cocaine-taking and cocaine-seeking behaviors in the rat. Psychopharmacology (Berl) 2005;183(1):41–53.
Dias C, Lachize S, Boilet V, Huitelec E, Cador M. Differential effects of dopaminergic agents on locomotor sensitisation and on the reinstatement of cocaine-seeking and food-seeking behaviour. Psychopharmacology (Berl) 2004;175(4):414–27.
de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 2001;12(16):3533–7.
Ferraro L, Fuxe K, Agnati L, Tanganelli S, Tomasini MC, Antonelli T. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. Synapse 2005;55(4):230–41.
Ferraro L, Fuxe K, Tanganelli S, Fernandez M, Rambert F, Antonelli T. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000;39(11):1974–83.
Machado-Vieira R, Salvadore G, DiazGranados N, Zarate Jr CA. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009;123(2):143–50.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mahmoudi, J., Farhoudi, M., Talebi, M. et al. Antidepressant-like effect of modafinil in mice: Evidence for the involvement of the dopaminergic neurotransmission. Pharmacol. Rep 67, 478–484 (2015). https://doi.org/10.1016/j.pharep.2014.11.005
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2014.11.005